{"links":{"feed":"https://www.erudio.com/reports/harmoni-3-nct05899608/feed.json","html":"https://www.erudio.com/reports/harmoni-3-nct05899608","json":"https://www.erudio.com/reports/harmoni-3-nct05899608.json","markdown":"https://www.erudio.com/reports/harmoni-3-nct05899608.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"harmoni-3-05899608"}},"request":"https://www.erudio.com/contact?report=harmoni-3-05899608"},"offer":{"cited_clinicians":21,"cited_commentary_sources":97,"verified_hcp_statements":286,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified speaker identities: the verified IDs of the people in the report, led by the NPI or their institution's staff page, so a Medical Affairs team can check that each statement is attributed to the right person: also X, Bluesky, LinkedIn and other web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For checking attribution inside the organization; never for outreach to or targeting of clinicians. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":27,"optional":true,"price_per_verified_person_usd":15,"price_usd":405,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"harmoni-3-nct05899608"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=harmoni-3-05899608","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/harmoni-3-nct05899608","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_line":"Standard · 286 verified statements · 114 from 21 confirmed clinicians","size_rule":"Standard: 151–300 verified statements. Standard and Deep need at least 5 confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); with fewer, a report is sold one size down.","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-04T09:39:45.611888Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":47,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":28,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":38,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":21,"title":"Primary endpoint: Progression Free Survival (PFS)"},{"claim_count":22,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":10,"title":"Secondary endpoint: Adverse Event (AE)"},{"claim_count":37,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":21,"title":"Population and setting"},{"claim_count":36,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":18,"title":"The comparison"},{"claim_count":28,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":15,"title":"Safety and tolerability"},{"claim_count":28,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":19,"title":"Design and conduct"},{"claim_count":34,"coverage":"discussed","id":"A1","source_count":24,"title":"Global transferability, age and representativeness"},{"claim_count":17,"coverage":"discussed","id":"A2","source_count":15,"title":"Bispecific rationale and the incremental contribution of VEGF blockade"},{"claim_count":37,"coverage":"discussed","id":"A3","source_count":18,"title":"PD-L1-guided treatment choice and reasons to omit chemotherapy"},{"claim_count":2,"coverage":"discussed","id":"A4","source_count":1,"title":"Molecular work-up before systemic treatment selection"},{"claim_count":13,"coverage":"discussed","id":"A5","source_count":4,"title":"Competing ADC-based first-line strategies"},{"claim_count":45,"coverage":"discussed","id":"A6","source_count":22,"title":"Clinical adoption and regulatory evidentiary thresholds"},{"claim_count":16,"coverage":"discussed","id":"A7","source_count":13,"title":"Local research access and anticipation"}],"counts":{"cited_clinicians":21,"cited_clinicians_by_role":{"pharmacist":1,"physician":6,"physician, Hematology and oncology":1,"physician, Medical oncology":13},"cited_physicians":20,"cited_sources":98,"claims_by_expression_type":{"comparison":23,"experience":2,"interpretation":81,"opinion":75,"primary_context":1,"question":21,"restatement":21,"uncertainty":23,"unspecified":39},"claims_by_kind":{"interpretation":6,"protocol_statement":1,"source_observation":279},"clinician_statements":114,"evidence_units":194,"findings":11,"organisational_accounts":21,"people_cited":41,"people_identity_verified":27,"people_total":43,"screened_sources":142,"verified_claims":286},"findings_index":[{"id":"F1","structure":{"claims":21,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":0,"views":17},"has_counterview":true,"limitations":3,"links":{"context":5,"support":22},"ma_question":true,"named_voices":7,"passages":18,"sources":8,"sources_by_kind":{"commentary":3,"media":5}},"title":"Clinicians welcome regional efficacy signals but still await global evidence before changing routine practice"},{"id":"F2","structure":{"claims":16,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":1,"views":12},"has_counterview":true,"limitations":3,"links":{"context":1,"support":18},"ma_question":true,"named_voices":12,"passages":16,"sources":10,"sources_by_kind":{"commentary":7,"media":3}},"title":"Clinicians find squamous-disease safety reassuring with careful selection, not evidence of zero bleeding risk"},{"id":"F3","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":1,"views":8},"has_counterview":true,"limitations":3,"links":{"context":1,"support":13},"ma_question":true,"named_voices":7,"passages":12,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"Clinicians disagree over how much Chinese efficacy should be discounted before global confirmation"},{"id":"F4","structure":{"claims":20,"claims_by_group":{"comparisons":0,"experience":0,"questions":5,"restated":4,"views":11},"has_counterview":true,"limitations":3,"links":{"context":3,"support":20},"ma_question":true,"named_voices":7,"passages":12,"sources":7,"sources_by_kind":{"commentary":7}},"title":"One pharmacist reads the interim update as inconclusive but concerning; other commentators differ over what it implies"},{"id":"F5","structure":{"claims":15,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":0,"views":11},"has_counterview":true,"limitations":3,"links":{"context":0,"support":17},"ma_question":true,"named_voices":9,"passages":16,"sources":11,"sources_by_kind":{"commentary":10,"media":1}},"title":"Clinicians prioritize survival, while two clinicians differ over possible EU approval before global results"},{"id":"F6","structure":{"claims":12,"claims_by_group":{"comparisons":3,"experience":0,"questions":2,"restated":0,"views":7},"has_counterview":true,"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":6,"passages":7,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"One pharmacist defends the chemotherapy control while asking whether bispecific linkage adds synergy"},{"id":"F7","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":2,"questions":1,"restated":3,"views":5},"has_counterview":true,"limitations":3,"links":{"context":3,"support":13},"ma_question":true,"named_voices":5,"passages":9,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"Episode commentary favors chemotherapy for most PD-L1-low patients and gives explicit reasons to omit it"},{"id":"F8","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"media":1}},"title":"One clinician calls NGS essential regardless of histology or tobacco exposure"},{"id":"F9","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":8},"has_counterview":true,"limitations":3,"links":{"context":1,"support":12},"ma_question":true,"named_voices":8,"passages":13,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"Whether histology or PD-L1 predicts the benefit HARMONi-3 will show"},{"id":"F10","structure":{"claims":10,"claims_by_group":{"comparisons":5,"experience":0,"questions":1,"restated":1,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":5,"passages":9,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Speakers see competing first-line strategies, but their views do not establish a head-to-head winner"},{"id":"F11","structure":{"claims":17,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":8,"views":6},"has_counterview":true,"limitations":4,"links":{"context":0,"support":17},"ma_question":true,"named_voices":11,"passages":13,"sources":13,"sources_by_kind":{"commentary":12,"media":1}},"title":"One account sees histology separation as potential de-risking and asks what motivated it"}],"medical_affairs_question":"What global survival benefit, in which patients and with what selection-dependent harm, would justify replacing the current first-line backbone?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. Enthusiasm is not the same as readiness to replace the backbone"},{"id":"section-2","level":2,"title":"2. Reassuring safety remains attached to selection and nonzero harm"},{"id":"section-3","level":2,"title":"3. The global-transfer debate is more specific than geography alone"},{"id":"section-4","level":2,"title":"4. The interim miss generates competing models, not a disclosed effect estimate"},{"id":"section-5","level":2,"title":"5. Survival expectations must be separated from regulatory rules"},{"id":"section-6","level":2,"title":"6. The comparator debate asks what the trial can actually distinguish"},{"id":"section-7","level":2,"title":"7. Treatment selection includes reasons not to add chemotherapy"},{"id":"section-8","level":2,"title":"8. Molecular testing is part of the first-line decision, including in squamous disease"},{"id":"section-9","level":2,"title":"9. Subgroup interest does not establish a predictive treatment rule"},{"id":"section-10","level":2,"title":"10. ADC-based alternatives prevent a class-only interpretation"},{"id":"section-11","level":2,"title":"11. Amendments, access and timing attract different kinds of attention"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":7},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":7},{"id":"F7","shared_claims":2},{"id":"F9","shared_claims":4},{"id":"F11","shared_claims":2}],"id":"T1","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":19},{"id":"F5","shared_claims":1},{"id":"F9","shared_claims":3},{"id":"F11","shared_claims":2}],"id":"T2","label":"Primary endpoint: Progression Free Survival (PFS)"},{"findings":[{"id":"F2","shared_claims":12},{"id":"F9","shared_claims":1}],"id":"T3","label":"Secondary endpoint: Adverse Event (AE)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":10},{"id":"F7","shared_claims":6},{"id":"F8","shared_claims":2},{"id":"F9","shared_claims":7},{"id":"F10","shared_claims":1},{"id":"F11","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":11},{"id":"F7","shared_claims":3},{"id":"F9","shared_claims":1},{"id":"F11","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":16},{"id":"F3","shared_claims":3},{"id":"F5","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":1},{"id":"F11","shared_claims":15}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-04T09:39:45.611888Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-04T09:53:22Z","record_hash":"6e058a3c1af2067c1a646f0bd9400f31d3941aa064b7510f49bbba43147e6929","release_hash":"ac832e38b51895a7c2bdb453096f84e9ae6273eb29e4ad307428ab868692f383","report_id":"erudio-nct05899608","run_id":"c6260b6f-8aea-4422-8da6-3defd975c32d","schema_version":"5.0","slug":"harmoni-3-05899608","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"HARMONi-3 compares ivonescimab plus chemotherapy with pembrolizumab plus chemotherapy in first-line metastatic non-small cell lung cancer; the discussion weighs regional benefit signals against the need for global confirmation before changing practice. The report cites 20 physicians, including 13 medical oncologists, and one pharmacist. Further questions concern selection-dependent bleeding risk in squamous disease and whether histology or PD-L1 predicts benefit. What survival benefit worldwide, for which patients and with what harm linked to patient selection, would justify replacing pembrolizumab plus chemotherapy?","meta_description":"142 sources screened · 286 verified statements (114 from clinicians verified by NPI or staff page) from 98 sources · 11 findings. Updated Nov 4, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-5befa48482f2529e0f18","claim-35cae21126ce2ac90019"],"id":"F6","paraphrase":"A pharmacist's LinkedIn post raises questions about adding bevacizumab to the comparator and whether linking antibody targets creates synergy.","publication_caveats":{"reason":"Further publication restrictions are not specified in the sources reviewed for this edition.","status":"not_set"},"source_channel":"linkedin_post","source_date":"2025-04-22","title":"One pharmacist defends the chemotherapy control while asking whether bispecific linkage adds synergy"},{"cited_claim_ids":["claim-fcd59f929cc3a41e6bdf"],"id":"F11","paraphrase":"An X thread asks why HARMONi-3 adopted histology-specific analyses and whether signals from other studies informed that decision.","publication_caveats":{"reason":"Further publication restrictions are not specified in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2025-10-20","title":"One account sees histology separation as potential de-risking and asks what motivated it"}]},"publication":{"approved_at":"2026-11-04T09:53:22Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":142},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Not yet captured in this edition: a view on global applicability, patient selection and VEGF-related toxicity in first-line ivonescimab-based treatment.","Not yet captured in this edition: a view on immunotherapy plus an ADC as an emerging first-line NSCLC treatment alternative.","Not yet captured in this edition: a view on immunotherapy plus an ADC as an emerging first-line treatment alternative in non-small cell lung cancer.","1 more clinician view in the sources used in this report is not yet captured as evidence in this edition.","131 passages in 90 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","67 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 70 sources about other trials or topics are not included.","The sources reviewed for this edition are a selected collection, not a representative sample of HCP opinion. Repeated posts, relays and overlapping recordings do not establish additional independent speakers or consensus.","Some potentially relevant passages were not fully assessed. Discussions that did not use recognizable trial names or that were transcribed differently may be missing, so the report cannot claim exhaustive coverage.","Several passages, particularly on the September 2024 episode and in a short recap video, cannot be assigned to named speakers. They may belong to participants already discussed and are not counted as separate people.","The material mixes clinical discussion with author, organization and investment-account commentary. A verified identity, a source-described credential or a dated affiliation does not establish expertise, independence or the truth of a view.","No exact HARMONi-3 results publication, complete protocol or statistical plan, or exact regulatory label was available. Interim thresholds, modeled success probabilities, approval expectations and historical amendments are therefore reported at the level the sources support.","Findings from HARMONi-2, HARMONi-6 and other studies are context for the first-line treatment question, not HARMONi-3 results. Cross-trial estimates, subgroup interpretations and different hemorrhage definitions cannot be combined into a single comparative conclusion.","Dates attached to posts or published recordings do not necessarily date the underlying session or readout. Different timing statements are kept as contemporaneous expectations, not interpreted as demonstrated changes of mind.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":3,"other":0,"podcast":3,"publication":0,"registry":1,"regulatory":0,"x_thread":88,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":97,"methods":1},"count":98,"evidence_window":{"end":"2026-10-28","start":"2023-10-14"},"retrieval_snapshot":"2026-11-04T08:18:55.858390Z","timeline":[{"count":2,"week":"2023-W41"},{"count":1,"week":"2024-W36"},{"count":1,"week":"2024-W38"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W46"},{"count":3,"week":"2025-W17"},{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W37"},{"count":3,"week":"2025-W42"},{"count":5,"week":"2025-W43"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2025-W51"},{"count":2,"week":"2026-W09"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W17"},{"count":6,"week":"2026-W18"},{"count":3,"week":"2026-W19"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W21"},{"count":20,"week":"2026-W22"},{"count":8,"week":"2026-W23"},{"count":1,"week":"2026-W24"},{"count":2,"week":"2026-W25"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W35"},{"count":2,"week":"2026-W36"},{"count":2,"week":"2026-W37"},{"count":6,"week":"2026-W38"},{"count":2,"week":"2026-W39"},{"count":3,"week":"2026-W40"},{"count":2,"week":"2026-W41"},{"count":7,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":2,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05899608:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05899608:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4aeinxjwao74le6dktiiyxg4-3mrefbr7dao2e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3mrdnhafhlr2q","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7246533294371045376","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7320533252891381761","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7457119484323979264","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:20414b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b70be7","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e4dc3c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1653757924563472386:7db71ac9-7b35-440e-b39e-09a6ce9f79f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1713266634540937417:c89be28f-27dc-4316-853f-8106fac73e61","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1713471172300398829:3e132da6-5c62-4ac4-b6aa-94b687d6aa6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1744937674627236150:3850ec32-b141-4d77-aba9-543087449f0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1745818365334053222:a1c187ea-ea5f-4fed-b01a-724d22c645cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796383040064606387:c8af943a-ff73-4115-b83b-0eacab1b2f92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796664733694566633:e5acb07f-8707-40a7-a851-c6b079e5709d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1827909404626149611:90bd4c19-7b83-4799-8941-f7431d540fe0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832817641351938541:8c7998b5-30ab-45a7-8dba-024b835f8807","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1853358699017896009:c8ba22d3-2bc2-4632-a281-49b6c371c6f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1857265081534283965:a9226628-0776-411d-8750-6d68d37e3c76","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1879168998253740224:f6ddb1c4-d537-4a5e-8200-5407bf3dd9eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1893996271179845953:1d250ecb-7f7e-4e10-8e78-7664d783775f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915047836812787863:022b520f-cc87-4c20-b2c9-90a90b8d1528","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915162374828412953:30888506-bfe0-4c75-a3af-43aed71c4cfc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915850511015940456:b4a75a49-7e8b-439d-93b3-e4ddaed39fde","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925974003216208046:a439a868-1665-4f85-8b6f-b5c19d2cf158","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925978191622987925:793c5892-8ed9-4e42-a786-81ab1abc4ad3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1927111647186866579:7b8ca42f-8338-4864-bf9e-4383d6239e41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1959138283100815517:93d693e8-c4f1-419a-9921-f44f1ea0b2c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964778181564719534:0af485ad-19d6-4688-b9f0-c27bd66a5cc2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979794241175072854:32fb656f-c0e9-4d5d-ae98-ef5f1a34cf02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979919943836504422:53b6a246-1735-4588-9b18-4d71667d3b8e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979925489385939041:76ce356a-a075-4758-8f17-539f3816cc48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979956616318587175:437deec9-ae5b-4f19-8bb3-fb959ae75e74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979959549713858927:8c5119ce-af4b-4242-8d9e-43a27db8df8f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980161238421414259:45a541cc-1a74-4e81-9fea-ed57c11cb43f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980197665804800191:3e725768-bd4b-4312-bbfc-c09e457321d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980228925172367485:e305c78a-25ec-4caa-9e39-7976ead92484","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980230982562455953:da67ddff-5d9d-4df7-8785-c18215c47e92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981054806299955355:a2a79259-87bb-449d-8d1e-c9224b09f0f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981064427630973013:7a1ca693-1114-48d4-90a6-cfb54e725a38","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981313973203911067:ac3af434-e68b-4250-90f9-8092c823b1e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1983117481645691133:5a70d6b1-bcd7-4b43-b10d-f8c48cfb8020","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001977569600569718:92492d46-03ba-48ad-b5be-76b0059598ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011166506860560448:27e6b1b0-137a-4c9a-9c14-e2bf3e183e37","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2026043310922465655:eaa8ea8f-88db-40b4-95f6-a947d0856130","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2026141884075458908:56bf4148-0714-47bc-8df8-117652276e74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2026318090825506827:fe3eb6da-45a9-4418-b635-50fa6090f698","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2026342149827002821:7eadd1bc-bb39-4bd7-9dc0-6cb3d40ee3c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2026369572874457155:c9d6d68a-6e86-45fd-a554-8a8a2f3eea8e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027164402361741668:2542d27c-6116-449f-95a0-8e5e0c0f3ebe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027410178916696502:9f757861-2902-4f83-b168-d096cd2c72a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032945077400858708:9aa3ecba-e653-4574-8b9d-1e231bbd90ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2035004864896643119:8fe25982-c605-4f4d-9fb5-88429a52b125","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037850267018822098:89f3e553-b5a6-4e95-a2a8-bb153d8fb2e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2041497765717610575:119f7939-740a-45b7-88bb-5c362944d18a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047617333775233084:7aaa9ec5-3aad-4bcf-9fac-6c55b5d8a25a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049951515201167859:e5b8ca5d-af08-4568-9cf8-36f05a5f9b78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049967805747900517:4752e4bd-473e-4b21-a7a8-38b9f5729754","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050103896094241206:d6c84ca6-8eb0-4271-b33b-c766cb83fd57","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050176434157621641:75e86cb6-aacb-49a9-8be6-0aa66259c222","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050190476372840793:ae6efab0-a167-424d-8bb7-1a5d44ac016e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050223293467414673:a86afdf5-061b-468e-befb-7ac5c9aec7fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050245682938757453:9264d124-9d90-4e07-a882-38b96d49d756","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051293946987544891:52d3dbdb-3684-4bc2-a42c-8244fbc7f14e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051317802624057845:752be9ec-64b3-486a-8ac4-a14605aaf2cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053128898741698809:d38996d7-2406-4da0-beb3-db9e0b705918","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053414428658307180:c25dbb9c-ed3f-4eaf-9d84-6055e2c744be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2054842528587764065:beecd3a6-9285-494d-9050-4f1207fc74fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058501723421843828:96d7f358-cf5e-4742-8065-f0102bea1035","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059170263510765583:c7736033-9600-4c87-8794-60ed6c6c4b4e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060428469800980514:3b29bfaa-b996-49cd-8196-c6569d9fbb7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061055400305164515:a29fef32-a050-4ae7-a190-dafaf4146207","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061059126806098199:c31e53f2-b924-416e-b24a-6033965b4ef6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061061749609034067:a6bf84fd-6ee6-4d2e-9be2-0dfbf54fae0b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061067531951988791:4baa74de-94b1-4846-8334-cd5fd2d54ed0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061081424623771861:3f31c54f-0207-4583-8544-bea9a8451beb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061081600021188639:f7d84473-1a62-4fc2-9f8b-31577bb04a86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061114530638549136:03ffc5c8-ef8c-4314-8859-ce508cc692ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061119223716536338:028f9b51-7099-4508-aefd-a1fc4c0569b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061175309282537789:5a430090-ebe5-439c-bd03-309ddbe4b49b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061175509753405891:2d9b1703-aed8-435d-9e96-e9569952b1af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061175561494397165:4051657d-077d-4a7d-88ec-08556d9bcda3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061176231954120952:63c2879f-1d8f-421e-b570-23ce424bce3a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061176659059843177:a0acc601-653c-4e48-8119-5a55c6a57abb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061176894624821485:4753db66-d6c9-4db9-b3a1-2e31f9019315","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061177029240696833:905bb78f-c8db-4be6-a262-ac4dfae95d70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061177125214838990:867b6999-33b9-4594-bb3d-dd792ba60b14","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061177350453092439:99971b34-bd99-4876-828e-e182065700bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061179097435226587:7378ad12-0e4f-40cc-b481-7bd0f7ea647e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061179629273030998:3d7b4b5b-7281-4dbe-9c90-479ad60f1a0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061183732518645904:13c8bd57-911e-44c7-8c07-d0b249a4f947","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061203503515590932:43a8ffac-3287-4773-a0c9-509e15d03f1e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061253899785290216:6586a60f-5ad8-49d4-9268-7ea31d36c25a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061270271554891848:d25c3efc-b729-4253-9cf3-64cb59d61750","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061441747662582050:b023c03c-481c-4571-8720-27aed5a1b798","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061803757143466242:0d31f906-0689-4c85-bc24-70f76854c40d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062146265102561668:13ec734a-b6a7-4662-b0a9-7a7ba16b3dd3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064109601553777131:b65ef921-9063-4720-b81c-6dcd4e3aa432","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065227385142645165:93b7e352-0f45-4a2f-8a3e-f92b93867b38","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066823192338153927:12b89378-7a9b-49e3-8ed0-b3c38b30edf8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066979405134520420:35982564-ddc2-43b6-a8a9-57d669cadb75","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080385373679518103:0b8bc9f7-b361-4811-b1e4-3e77ae0f76c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084191364774859194:71ac7ec9-0532-4e5f-bb19-bcd81c5889d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085593966032863423:62a278e3-7659-441e-a3c4-44152124f08d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087530457277575540:3c114e81-c464-433f-8f35-0622f5adbeab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092236873082995168:51817421-cb31-4e4f-9810-714b183b2f45","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092702076799180823:1a15bd63-6fb8-4855-afa6-0e50716c301b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093363265132728759:7826ef83-5dd7-43ba-bf4a-fd0e12ca97ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095607859379585064:d2ea183f-bd83-42d7-9399-d0823e35f327","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096730851388371084:3054c1aa-ac32-46e0-be4f-230027e1dd7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096732159788921121:af7fc22c-a16e-4266-9803-73401f53290e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097032484806398149:4d2bafde-b93f-4524-8f26-45590553a287","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099122205858611543:709eae6a-8475-4f81-ae97-1eb6ab2f831e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099277627135758551:cee027eb-1422-4111-8c0d-313a5990dfea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099406729939497231:1988d067-9a79-429e-a03c-21900f0b4117","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099474079938126094:7fb0628f-3262-45ca-87c5-662ca2784c46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099834726324527558:df5aa59d-dafd-4c81-b123-91cfb42cd4cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100138205458612657:8e2e7ecc-e5ab-4970-8d7c-4cc7eddfb94c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102431113561919872:7e947881-cc5b-4b98-bfe8-98a664e8433a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103609858729664967:f89e3129-497f-4e81-8714-a86f9e3dda7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104889112511611197:d4708482-66ba-42c9-b6b9-512fe2892753","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105369364824551821:5c3c5608-7d9e-42ee-b1a5-f9b3a6575add","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106006942590152943:1b7cae1c-9380-4e2a-9318-26d83ca566a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106382651418615942:0710b7ec-cfb0-492d-9911-4227d1b2a13c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107289582337220810:1bd3fd68-11f0-4852-9580-e45def5c3fbc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107537957590802754:b330dcb1-0b29-4ea1-82ec-2d0c9c83523f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108971304321785975:1339933b-c94b-437a-a85f-d420617b5661","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109010253110993020:b72f164c-3043-4b21-bedf-f0e99e2e9aed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110409007290798290:02082246-f1f7-4017-9b0f-90d3a95c5b12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110430476548624812:fe91101e-7a87-4234-a3c5-c025887a2672","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110768371595923468:67881cd8-e46b-41ef-8fe1-64de62c51f04","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110784583730106606:3f13e17f-3ad9-487e-827d-e73024c8fef2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110785495684743502:3cd5e350-9dd5-427d-bf4a-a085c0085544","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112802236703097078:3da68dd7-88a6-4222-aee7-c1399f59c6a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113684285014307078:68d6daf3-219c-411e-a668-9a5b02f97678","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114401724714934556:528f7df1-86e5-43d8-bdbb-189a9b61608f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114402745406939519:033c5d21-dd59-4ad5-a51f-bd4ef94b9cf9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115091903628574848:f1a8c695-7074-45a3-882d-88d1ad4c17d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115398173971579010:47b77e14-b76d-4eeb-b3d5-4bcff717795b","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:1IkOC4mhGy8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4w8OOqf806w","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:L_OoTt0n80w","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":3,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":131,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":142},"count":142,"evidence_window":{"end":"2026-10-28","start":"2023-05-03"},"retrieval_snapshot":"2026-11-04T08:18:55.858390Z","timeline":[{"count":1,"week":"2023-W18"},{"count":2,"week":"2023-W41"},{"count":2,"week":"2024-W02"},{"count":2,"week":"2024-W22"},{"count":1,"week":"2024-W35"},{"count":1,"week":"2024-W36"},{"count":1,"week":"2024-W38"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W09"},{"count":4,"week":"2025-W17"},{"count":2,"week":"2025-W21"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W36"},{"count":1,"week":"2025-W37"},{"count":5,"week":"2025-W42"},{"count":7,"week":"2025-W43"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W03"},{"count":7,"week":"2026-W09"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W17"},{"count":7,"week":"2026-W18"},{"count":5,"week":"2026-W19"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W21"},{"count":24,"week":"2026-W22"},{"count":9,"week":"2026-W23"},{"count":2,"week":"2026-W24"},{"count":3,"week":"2026-W25"},{"count":3,"week":"2026-W30"},{"count":2,"week":"2026-W32"},{"count":1,"week":"2026-W33"},{"count":3,"week":"2026-W35"},{"count":3,"week":"2026-W36"},{"count":3,"week":"2026-W37"},{"count":6,"week":"2026-W38"},{"count":2,"week":"2026-W39"},{"count":4,"week":"2026-W40"},{"count":4,"week":"2026-W41"},{"count":7,"week":"2026-W42"},{"count":4,"week":"2026-W43"},{"count":2,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: ivonescimab injection","status":"unmapped"},{"reason":"Unmapped registry intervention: pembrolizumab injection","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"HARMONi-3","aliases":["HARMONi-3","Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients","A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)"],"brief_title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small Cell Lung Cancer"],"display_condition":"first-line metastatic non-small cell lung cancer","display_interventions":[["ivonescimab"]],"enrollment":{"count":1600,"type":"ESTIMATED"},"interventions":[{"name":"Ivonescimab Injection","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"},{"name":"Pembrolizumab Injection","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"}],"nct_id":"NCT05899608","official_title":"A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"primary_endpoints":[{"description":"Overall Survival (OS) in the ITT population","measure":"Overall Survival (OS)","timeFrame":"approximately 4 years"},{"description":"Progression Free Survival (PFS) assessed by investigator based on RECIST V1.1","measure":"Progression Free Survival (PFS)","timeFrame":"approximately 3 years"}],"registered_date":{"date":"2023-06-12","type":"ACTUAL"},"registry_last_updated":"2026-10-08","registry_url":"https://clinicaltrials.gov/study/NCT05899608","short_name":"HARMONi-3","short_name_basis":"canonical_name","sponsor":"Summit Therapeutics","start_date":{"date":"2023-10-26","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"SMT112-3003","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}